Availability of ozanimod

In March 2020, the U.S. Food and Drug Administration (FDA) approved ozanimod for the treatment of relapsing multiple sclerosis in adults. The European Commission approved ozanimod in May 2020 for the treatment of adult patients with relapsing-remitting multiple sclerosis who have active disease as defined by clinical or imaging features. The FDA approved Ozamod on May 27, 2021, for the treatment of adults with moderately to severely active ulcerative colitis. Ozamod (ozanimod)The original drug was approved by the State Food and Drug Administration on January 31, 2023 and was launched in the country. It is named Ozamod Hydrochloride Capsules and the trade name is Repersia. However, it has not been included in the medical insurance list for a short time on the market.